Return to Trial Database

GU00-9

A Multicenter Randomized Phase II Study of Docetaxel plus Vinorelbine and Doxetacel plus Estramustine in Combination for Hormone Refractory Prostate Cancer

Status

Study Completed

Cancer Type(s)

Study Contact

Publications

A Multicenter Randomized Phase II Study of Docetaxel (D) plus Vinorelbine (VRB) and Docetaxel plus Estramustine (EMP) in Combination for the Treatment of Hormone Refractory Prostate Cancer (HRPC)

Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis

Trial Locations

All sites in which the trial GU00-9 being conducted in.

No data was found